Cefriaxone Sodium powder for Injection Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a compendial active pharmaceutical ingredient conforming to the USP-NF and Ph.Eur. monographs for ceftriaxone sodium. The substance is the disodium hemiheptahydrate salt of the third-generation cephalosporin, with CAS registration 74578-69-1, molecular formula C18H16N8Na2O7S3·3.5H2O, and relative molecular mass 661.6 g/mol. The API is released as a white to faintly yellow crystalline powder with an assay specification of 98.0–102.0 % on the anhydrous basis. Two supply grades are commonly distinguished: a sterile micronized grade certified for aseptic filling into vials and a non-sterile bulk grade intended for further processing. The sterile grade is controlled for bacterial endotoxins, subvisible particulate matter, and sterility according to USP <71>, USP <85>, and USP <788>, whereas the non-sterile grade omits the sterility release test. The product descriptor includes tablet, capsule, and granule applications, but the oral solid-dosage statements require a critical pharmacokinetic interpretation because cefriaxone sodium is not recognized as an orally bioavailable cephalosporin.

What Limits Gastrointestinal Absorption and Solid-Dosage Compatibility of Cefriaxone Sodium?

Oral absorption of cefriaxone sodium is negligible because the molecule is a highly ionized, zwitterionic cephalosporin with poor passive transcellular permeation, lacks a prodrug ester, and undergoes acid-catalyzed beta-lactam ring opening in the gastric environment. Consequently, published data for cefriaxone sodium tablets, capsules, or granules intended for human oral administration is limited, and no pharmacopoeial monograph exists for such oral dosage forms. In contrast, oral cephalosporins such as cephalexin, cefixime, and cefuroxime axetil are absorbed via peptide transporters or are furnished as prodrug esters, whereas cefriaxone sodium requires parenteral administration. Any attempt to formulate cefriaxone sodium as an oral solid dosage form would need to address particle-size distribution, acid protection, and absorption enhancement; no reliable clinical evidence establishes therapeutic equivalence to the injectable route.

Compendial Release Specifications and Critical Physicochemical Thresholds

The pharmacopoeial release panel includes identification, water content, pH, assay, related substances, residual solvents, elemental impurities, bacterial endotoxins, and, for sterile grade, sterility and subvisible particulate matter. Water content is specified at 8.0–11.0 % w/w for the hemiheptahydrate form; excursions outside this range can alter stoichiometry and reconstitution behaviour. The pH of a 10 % aqueous solution is specified at 6.0–8.0; values outside this interval may indicate beta-lactam degradation or salt disproportionation. Assay is determined by HPLC against a pharmacopoeial reference standard and reported as 98.0–102.0 % on the anhydrous basis, with total related substances bounded by the monograph limits for ceftriaxone sodium. Residual solvents are controlled according to ICH Q3C and USP <467>; the specific residual solvent profile depends on the crystallization and drying solvent system used in the final purification step. Elemental impurities are controlled according to ICH Q3D Option 1 using USP <232>/USP <233> or Ph.Eur. 2.4.20. The bacterial endotoxin limit for the sterile grade is 0.20 EU/mg or less by USP <85> or Ph.Eur. 2.6.14. Subvisible particulate matter for a reconstituted small-volume parenteral should satisfy USP <788> limits of 6000 particles/container at ≥10 µm and 600 particles/container at ≥25 µm by light obscuration. These limits define the operational boundaries for injectable formulation and aseptic filling rather than serving only as release formalities.

When Cefriaxone Sodium Is Processed on Aseptic Dry-Powder Filling Equipment

Processing of cefriaxone sodium sterile powder is normally performed in controlled low-humidity environments because the hemiheptahydrate form can gain or lose water in response to ambient moisture. Aseptic dry-powder filling lines for cephalosporin APIs are typically operated at 20–25 °C with relative humidity at or below 35 % RH; excursions above 40 % RH can increase powder cohesion, reduce flow through auger or vacuum-type dosing heads, and produce variable fill weights. On production-scale equipment, static charge accumulation on stainless-steel and polytetrafluoroethylene contact surfaces is minimized by grounding, conductive footwear, and humidity that is not allowed to fall below 20 % RH, because excessively dry conditions can increase triboelectric charging and particle adhesion to hopper walls. The powder is filled into Type I borosilicate glass vials under Grade A unidirectional airflow with Grade B background, as prescribed in EU GMP Annex 1 and related PIC/S guidance for sterile products. Terminal sterilization is generally not applied because cefriaxone sodium undergoes degradation in aqueous solution and is sensitive to high absorbed doses of ionizing radiation; therefore, sterile API and aseptic filling constitute the reference manufacturing route. Batch-to-batch variation in bulk density for crystalline cephalosporin powders often falls within 0.40–0.60 g/mL, affecting auger dosing accuracy and requiring adjustment of fill depth and vibratory feed amplitude; however, lot-specific values should be taken from the manufacturer’s certificate of analysis.

Stability of the dry powder is supported by storage at 15–25 °C in tightly closed containers protected from light. Reconstituted solutions should be used immediately or stored at 2–8 °C for no more than 24 h where compatibility has been demonstrated. The beta-lactam ring exhibits maximum stability near pH 6.5, with accelerated degradation below pH 5 and above pH 8; therefore, wet granulation with aqueous binders would present a hydrolysis risk if oral granules were attempted. Dry granulation by roller compaction under controlled relative humidity may be the only realistic solid-dosage conversion route, but no pharmacopoeial standard defines acceptance criteria for cefriaxone sodium tablets or capsules, and oral bioavailability remains an unresolved limitation.

Ceftriaxone Sodium Relative to Cefotaxime, Ceftazidime, and Oral Cephalosporins

Cefriaxone sodium is a third-generation parenteral cephalosporin with a longer elimination half-life than cefotaxime. The half-life in adults is reported as approximately 6–8 h, permitting once-daily dosing for many indications, whereas cefotaxime requires dosing every 6–8 h and ceftazidime every 8–12 h for systemic infections. Protein binding of cefriaxone is concentration-dependent and high, at approximately 85–95 %, while cefotaxime is about 36 % protein-bound and ceftazidime about 10 %. This high protein binding can displace bilirubin in neonates, which contributes to neonatal cautions and the contraindication of ceftriaxone-calcium coadministration. Cefriaxone demonstrates reliable activity against Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, and many Enterobacterales, but it lacks clinically useful activity against Pseudomonas aeruginosa compared with ceftazidime or cefepime. Unlike cefotaxime and ceftazidime, cefriaxone is eliminated by both renal and biliary pathways; approximately 33–67 % is excreted unchanged in urine and the remainder via bile. This dual elimination reduces the magnitude of dose adjustment in mild to moderate renal impairment, but combined severe hepatic and renal failure requires dose modification and monitoring. Compared with oral cephalosporins such as cefixime or cephalexin, cefriaxone sodium is not orally absorbed and is supplied only as a sterile powder for injection; therefore, the oral tablet/capsule/granule designation in the product description should be interpreted as a bulk-API handling category rather than an approved oral dosage form.

The API must not be compounded with calcium-containing diluents in neonates because of the risk of ceftriaxone-calcium precipitation in pulmonary and renal tissues. The powder should not be exposed to strong acids, strong bases, or oxidizing agents. In the same infusion container, cefriaxone sodium is physically or chemically incompatible with aminoglycosides, and separate administration lines are required. The beta-lactam ring is sensitive to hydrolysis by beta-lactamases; therefore, the product has no clinically relevant activity against methicillin-resistant Staphylococcus aureus or Enterococcus spp. Published data for the use of cefriaxone sodium in oral tablets, capsules, or granules for human therapy is limited, and clinical administration remains confined to the injectable route.